UTHR Stock Analysis: United Therapeutics | NASDAQ
Drug Manufacturers - Specialty & Generic | NASDAQ, USA | Market Cap: 20.825m USD | 12M Return: 22.2% | US91307C1027 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 370M
EPS Trend: 95.2%
Qual. Beats: 0
Rev. Trend: 95.0%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company that develops and commercializes therapies for chronic and life-threatening conditions, with a primary focus on pulmonary arterial hypertension (PAH). Its commercial portfolio includes Tyvaso DPI, Nebulized Tyvaso, Remodulin, Orenitram, and Adcirca for PAH, along with Unituxin for high-risk neuroblastoma and the Remunity Pump delivery system.
The company is headquartered in Silver Spring, Maryland, was founded in 1996, and operates in the United States and internationally. Its business model combines marketed specialty therapeutics with an extensive development pipeline that includes next-generation PAH therapies (RemunityPRO Pump, Ralinepag), expanded indications for existing products, and a regenerative medicine program featuring xenotransplantation and organ products such as UKidney, UHeart, miroliver, and mirokidney. United Therapeutics maintains licensing and collaboration agreements with partners including DEKA Research & Development, MannKind Corporation, and Arena Pharmaceuticals to support its product development efforts.
As a large-cap biotechnology company, United Therapeutics operates in the rare disease and specialty therapeutics segment of healthcare, generating revenue from a concentrated set of high-priced orphan drugs while investing heavily in long-cycle, high-risk research areas such as xenotransplantation and regenerative medicine.
- Tyvaso DPI revenue accelerates with PH-ILD label expansion
- Ralinepag Phase 3 trial results due in PAH market
- Xenotransplantation pipeline attracts premium biotech valuation
| Net Income: 1.31b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.15 > 0.02 and ΔFCF/TA 1.60 > 1.0 |
| NWC/Revenue: 91.17% < 20% (prev 107.2%; Δ -16.04% < -1%) |
| CFO/TA 0.23 > 3% & CFO 1.69b > Net Income 1.31b |
| Net Debt (-2.62b) to EBITDA (1.68b): -1.57 < 3 |
| Current Ratio: 5.73 > 1.5 & < 3 |
| Outstanding Shares: last quarter (45.8m) vs 12m ago -5.18% < -2% |
| Gross Margin: 86.14% > 18% (prev 88.98%; Δ -2.84% > 0.5%) |
| Asset Turnover: 41.70% > 50% (prev 38.92%; Δ 2.78% > 0%) |
| Interest Coverage Ratio: 132.1 > 6 (EBIT TTM 1.58b / Interest Expense TTM 12.0m) |
| A: 0.40 (Total Current Assets 3.48b - Total Current Liabilities 607.8m) / Total Assets 7.22b |
| B: 1.27 (Retained Earnings 9.16b / Total Assets 7.22b) |
| C: 0.21 (EBIT TTM 1.58b / Avg Total Assets 7.56b) |
| D: 7.81 (Book Value of Equity 6.40b / Total Liabilities 819.8m) |
| Altman-Z'' = 16.36 = AAA |
| DSRI: 0.80 (Receivables 310.3m/379.3m, Revenue 3.15b/3.08b) |
| GMI: 1.03 (GM 88.98% / 86.14%) |
| AQI: 0.73 (AQ_t 0.25 / AQ_t-1 0.34) |
| SGI: 1.02 (Revenue 3.15b / 3.08b) |
| TATA: -0.05 (NI 1.31b - CFO 1.69b) / TA 7.22b) |
| Beneish M = -3.31 (Cap -4..+1) = AA |
As of October 04, 2026, the stock is trading at USD 541.70 with a total of 944,981 shares traded. Over the past week, the price has changed by +13.93%, over one month by +10.10%, over three months by -2.56% and over the past year by +22.16%.
Current recommended Stop Loss: 519.30 (which is 4.1% or 1.1 ATR below the current price).
United Therapeutics has received a consensus analysts rating of 4.40. Therefore, it is recommended to buy UTHR.
- StrongBuy: 9
- Buy: 3
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 637.9 | 17.8% |
P/E Trailing = 17.3966
P/E Forward = 16.4204
P/S = 6.6017
P/B = 3.3347
P/EG = 2.2213
Revenue TTM = 3.15b USD
EBIT TTM = 1.58b USD
EBITDA TTM = 1.68b USD
Long Term Debt = unknown (none)
Short Term Debt = 7.30m USD (from shortTermDebt, last fiscal year)
Debt = 37.6m USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -2.62b USD (calculated: Debt 37.6m - CCE 2.66b)
Enterprise Value = 18.2b USD (20.8b + Debt 37.6m - CCE 2.66b)
Interest Coverage Ratio = 132.1 (Ebit TTM 1.58b / Interest Expense TTM 12.0m)
EV/FCF = 16.65x (Enterprise Value 18.2b / FCF TTM 1.09b)
FCF Yield = 6.01% (FCF TTM 1.09b / Enterprise Value 18.2b)
FCF Margin = 34.65% (FCF TTM 1.09b / Revenue TTM 3.15b)
Net Margin = 41.56% (Net Income TTM 1.31b / Revenue TTM 3.15b)
Gross Margin = 86.14% ((Revenue TTM 3.15b - Cost of Revenue TTM 437.2m) / Revenue TTM)
Gross Margin QoQ = 87.30% (prev 82.93%)
Tobins Q-Ratio = 2.52 (Enterprise Value 18.2b / Total Assets 7.22b)
Interest Expense / Debt = 31.91% (Interest Expense 12.0m / Debt 37.6m)
Taxrate = 16.66% (262.1m / 1.57b)
NOPAT = 1.32b (EBIT 1.58b * (1 - 16.66%))
Current Ratio = 5.73 (Total Current Assets 3.48b / Total Current Liabilities 607.8m)
Debt / Equity = 0.01 (Debt 37.6m / totalStockholderEquity, last quarter 6.40b)
Debt / EBITDA = -1.57 (Net Debt -2.62b / EBITDA 1.68b)
Debt / FCF = -2.40 (Net Debt -2.62b / FCF TTM 1.09b)
Total Stockholder Equity = 6.50b (last 4 quarters mean from totalStockholderEquity)
RoA = 17.33% (Net Income 1.31b / Total Assets 7.22b)
RoE = 20.18% (Net Income TTM 1.31b / Total Stockholder Equity 6.50b)
RoCE = 23.97% (EBIT 1.58b / Capital Employed (Total Assets 7.22b - Current Liab 607.8m))
RoIC = 20.44% (NOPAT 1.32b / Invested Capital 6.46b)
WACC = 7.83% (E(20.8b)/V(20.9b) * Re(7.80%) + D(37.6m)/V(20.9b) * Rd(31.91%) * (1-Tc(0.17)))
Discount Rate = 7.80% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -76.24 | Cagr: -3.57%
[DCF] Terminal Value 75.71% ; FCFF base≈1.08b ; Y1≈1.11b ; Y5≈1.21b
[DCF] Fair Price = 499.6 (EV 18.8b - Net Debt -2.62b = Equity 21.4b / Shares 42.9m; r=8.35% [WACC [floored]]; 5y FCF grow 2.05% → 2.50% )
EPS Correlation: 95.16 | EPS CAGR: 16.33% | SUE: 0.80 | # QB: 0
Revenue Correlation: 95.01 | Revenue CAGR: 14.50% | SUE: -0.73 | # QB: 0
EPS current Quarter (2026-09-30): EPS=6.46 | Chg30d=+0.31% | Revisions=-21% | Analysts=13
EPS current Year (2026-12-31): EPS=26.07 | Chg30d=+0.10% | Revisions=-6% | GrowthEPS=-6.4% | GrowthRev=-1.3%
EPS next Year (2027-12-31): EPS=28.58 | Chg30d=-0.39% | Revisions=-56% | GrowthEPS=+9.6% | GrowthRev=+9.3%
[Analyst] Revisions Ratio: -32% (up=12, down=25)